Medtronic plc has its principal offices in Ireland, its operational headquarters in suburban Minneapolis, Minnesota and is the world's third largest medical device company. In 2015, at the time of its relocation, Medtronic had the largest market capitalization of any company in Ireland: its market cap was about $100 billion while the market cap for CRH, Ireland’s largest indigenous business, was $18.4 billion.Medtronic operates in more than 160 countries. The company employs 85,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents. Wikipedia.
Medtronic Inc. | Date: 2017-03-08
1. A stent comprising a cobalt-based alloy is disclosed. The cobalt-based alloy is free of nickel (Ni), and comprises 10-35 weight % metal member selected from the group consisting of platinum (Pt), gold (Au), iridium (Ir), osmium (Os), rhenium (Re), tungsten (W), palladium (Pd), tantalum (Ta), and combinations thereof; 16-21 weight % chromium (Cr); 0-12 weight % molybdenum (Mo); 0-3 weight % iron (Fe); and balance cobalt (Co). A stent comprising a molybdenum free cobalt-based alloy is also disclosed, comprising 10-35 weight % metal member selected from the group consisting of platinum (Pt), gold (Au), iridium (Ir), osmium (Os), rhenium (Re), tungsten (W), palladium (Pd), tantalum (Ta), and combinations thereof; 20-24 weight % chromium (Cr); 0-12 weight % nickel (Ni); 0-3 weight % iron (Fe); and balance cobalt (Co).
Medtronic Inc. | Date: 2017-01-18
Methods and apparatus are disclosed for filling a therapeutic substance or drug within a hollow wire that forms a stent. The stent is placed within a chamber housing a fluid drug formulation. During filling, the chamber is maintained at or near the vapor-liquid equilibrium of the solvent of the fluid drug formulation. To fill the stent, a portion of the stent is placed into contact with the fluid drug formulation until a lumenal space defined by the hollow wire is filled with the fluid drug formulation via capillary action. After filling is complete, the stent is retracted such that the stent is no longer in contact with the fluid drug formulation. The solvent vapor pressure within the chamber is reduced to evaporate a solvent of the fluid drug formulation. A wicking means may control transfer of the fluid drug formulation into the stent.
Medtronic Inc. | Date: 2017-04-19
A cardiotomy and venous blood reservoir (20) including a housing assembly (22), a downtube, and a bowl. The housing assembly forms a chamber. The downtube extends from an inlet port to a downstream end within the chamber. A diameter of the tube lumen increases to the downstream end. The bowl forms a floor surface shoulder (60), intermediate segment, and protrusion. The shoulder circumferentially surrounds, and is spatially above, the downstream end. The intermediate segment extends radially inwardly and downwardly from the shoulder to a bottom face. The protrusion extends radially inwardly and upwardly from the bottom face to a center that is aligned with the lumen and below the downstream end. The flared inner diameter of the lumen reduces fluid velocity as venous blood enters the reservoir. The bowl floor surface gently receives the incoming venous blood at the protrusion, and smoothly guides the blood flow.
Medtronic Inc. and Kyocera Corporation | Date: 2015-02-18
A feedthrough includes a sheet 938 having a hole 936, where the sheet includes a first material 916 that is a ceramic comprising alumina. The feedthrough further includes a second material 940 substantially filling the hole, where the second material includes a platinum powder mixture and an alumina additive. The platinum powder mixture includes a first platinum powder having a median particle size of between approximately 3 and 10 micrometers and a second platinum powder that is coarser than the first platinum powder and has a median particle size of between approximately 5 and 20 micrometers. The platinum powder mixture includes between approximately 50 and 80 percent by weight of the first platinum powder and between approximately 20 and 50 percent by weight of the second platinum powder. The first and second materials have a co-fired bond therebetween that hermetically seals the hole.
Medtronic Inc. | Date: 2016-04-13
A heart valve (10) that can be expanded following its implantation in a patient, such as to accommodate the growth of a patient and the corresponding growth of the area where the valve is implanted, and to minimize paravalvular leakage. In one aspect, the invention may maximize the orifice size of the surgical valve. The invention includes expandable implantable conduits (14) and expandable bioprosthetic stented valves. In one aspect of the invention, the valve may be adapted to accommodate growth of a patient to address limitation on bioprosthetic valve lifespans.
Medtronic Inc. | Date: 2015-06-24
A computer system receives, before a start of a trial of a medical therapy, data that configure the computer system to detect alert conditions indicative of occurrences of failure modes identified as being potentially associated with an institutional ethics committee such as an Institutional Review Board (IRB) that reviews the trial. Respective mitigation procedures are defined for the failure modes before the start of the trial. The mitigation procedures indicate procedures to mitigate occurrences of the failure modes. Furthermore, the computer system receives IRB activity data indicative of activities performed by the IRB. The computer system detects, based on the IRB activity data that one of the alert conditions has occurred. The alert condition is indicative of an occurrence of a given one of the failure modes. In response to detecting that the alert condition has occurred, the computer system outputs an alert.
Medtronic Inc. | Date: 2015-03-04
A method for manufacturing a stent, the method comprising forming a first ring having a plurality of peaks and a plurality of valleys; forming a second ring having a plurality of peaks and a plurality of valleys; connecting one of the peaks of the first ring to one of the valleys of the second ring; and deforming a portion of the connected peak of the first ring causing displacement of stent material at the deformed portion to create a recess relative to an adjacent non-deformed portion and an extension extending towards the second ring relative to an adjacent non-deformed portion.
Medtronic Inc. | Date: 2015-10-07
A system comprising a user interface 208 that receives a patient therapy adjustment to a parameter of a therapy program that defines electrical stimulation therapy delivered to the patient; and a processor 80 that identifies a posture state of the patient; and associates the patient therapy adjustment with the posture state when the patient therapy adjustment is within a range determined based on stored adjustment information for the identified posture state.
Medtronic Inc. | Date: 2015-01-07
A shield located within an implantable medical lead may be terminated in various ways at a metal connector. The shield may be terminated by various joints including butt, scarf, lap, or other joints between insulation layers surrounding the lead and insulation extension. The shield may terminate with a physical and electrical connection to a single metal connector. The shield may terminate with a physical and electrical connection by passing between an overlapping pair of inner and outer metal connectors. The metal connectors may include features such as teeth or threads that penetrate the insulation layers of the lead. The shield may terminate with a physical and electrical connection by exiting a jacket of a lead adjacent to a metal connector and lapping onto the metal connector.
Medtronic Inc. | Date: 2015-08-05
A computing system determines a prioritization of potential barriers to patients receiving a medical therapy from a health care provider based on correlation coefficients related to the impact each barrier has on the number of times the healthcare provider provides the medical therapy. The computing system can display a plurality of multiple-choice questions related to a plurality of barriers to patients receiving a medical therapy from a healthcare provider. The plurality of barriers include barriers related to: clinical evidence, reimbursements, physician economics, physician capacity and training level for the medical therapy, and treatment capacity. Furthermore, the computing system receives indications of user input indicating selected answers to the multiple-choice questions. Each of the answers to the multiple-choice questions corresponds to a quantitative value. The computing system generates, based on the quantitative values corresponding to the selected answers, one or more diagrams indicating relative severity of the barriers in preventing the patients from receiving the medical therapy from the healthcare provider. The computing system also provides an estimated ability of the healthcare provider to reduce the barriers and an action plan corresponding to actions the healthcare provider can take in order to increase the number of times the healthcare provider provides the medical therapy.